Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma


ABSTRACT

Purpose

B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor.

Patients and Methods

A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts. Treatment commenced with a 3-week dose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expansion.

Results

NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia (Richter transformation; n = 7), Waldenström macroglobulinemia (n = 4), and marginal zone lymphoma (n = 3). Venetoclax was generally well tolerated. Clinical tumor lysis syndrome was not observed, whereas laboratory tumor lysis syndrome was documented in three patients. Treatment-emergent adverse events were reported in 103 patients (97%), a majority of which were grade 1 to 2 in severity. Grade 3 to 4 events were reported in 59 patients (56%), and the most common were hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%). Overall response rate was 44% (MCL, 75%; FL, 38%; DLBCL, 18%). Estimated median progression-free survival was 6 months (MCL, 14 months; FL, 11 months; DLBCL, 1 month).

Conclusion

Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes. We determined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable response in MCL. Additional investigations including combination therapy to augment response rates and durability are ongoing.

INTRODUCTION

Dysregulation of apoptosis via overexpression of the antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2) is fundamental to the biology of several subtypes of non-Hodgkin lymphoma (NHL). The BCL-2 gene was first cloned in a lymphoid cell line and found to be a hallmark of the most common form of indolent NHL, follicular lymphoma (FL). BCL-2 is also overexpressed in approximately 30% of diffuse large B-cell lymphomas (DLBCLs), and amplification of chromosomal region 18q21 (which includes the BCL-2 locus) is frequently found in mantle cell lymphoma (MCL).

Venetoclax is a highly selective BCL-2 inhibitor with potent activity against FL, DLBCL, and MCL cell lines, as well as in a t(14;18)-carrying xenograft model. The M12-175 study is a first-in-human dose-escalation trial of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL; arm A) or NHL (arm B). The results in the CLL arm showed a 79% response rate, including 20% of patients...
Venetoclax Monotherapy in Patients With NHL

Achieving complete remission. The potency of venetoclax in patients with CLL was illustrated by the development of clinical tumor lysis syndrome (TLS) in three of the initial 56 patients. Clinical TLS is defined as occurrence of two or more metabolic abnormalities during the same 24-hour period as well as an increased creatinine level, cardiac dysrhythmia, seizure, or death. With adjustments to the dose ramp-up schedule, there were no more clinical TLS events in 60 additional patients with CLL enrolled. Venetoclax is now approved by the US Food and Drug Administration for the treatment of patients with CLL with chromosome 17p deletion who have received at least one prior therapy.

Here, we report the results for the NHL cohort of the M12-175 study. The objectives were to define the safety profile, maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and preliminary efficacy of venetoclax and determine a recommended phase II dose and schedule for future NHL studies.

PATIENTS AND METHODS

Study Design

Arm B of the M12-175 study enrolled patients with relapsed or refractory NHL between September 2011 and November 2014 and is ongoing. The data cutoff for this publication was April 5, 2016. The trial was conducted under the International Conference on Harmonisation Good Clinical Practice guidelines and according to the Declaration of Helsinki. A local institutional review or ethics board approved the study at each site. All patients provided written informed consent before participation.

Patient Eligibility

Detailed eligibility criteria are available in the protocol (Data Supplement). Briefly, patients were required to have adequate bone marrow function, an Eastern Cooperative Oncology Group performance status of 0 or 1, creatinine clearance ≥50 mL/min, liver transaminases ≤3 × the upper limit of normal, and bilirubin ≤1.5 × the upper limit of normal. One patient with multiple myeloma was enrolled early in the study, when the inclusion criteria permitted patients with other lymphoproliferative diseases. Patients were excluded if they had Burkitt or Burkitt-like lymphoma, lymphoblastic lymphoma or leukemia, post-transplantation lymphoproliferative disorder, active infection, previous allogeneic stem-cell transplantation (SCT) at any time, or autologous transplantation within 6 months of starting therapy. Antilymphoma therapy was not allowed within 14 days (8 weeks for monoclonal antibodies) before the first dose. Corticosteroids were allowed for a limited duration for medical indications other than antineoplastic intent.

Treatment

Venetoclax was administered orally once daily. Sequential dose-escalation cohorts of ≥three patients were accrued to a 3 + 3 design.10 Patients in the initial dose-escalation cohorts reached target daily doses of 200 to 1,200 mg. Safety expansion cohorts included only patients with FL and DLBCL, who received a target dose of 1,200 mg daily. Patients continued receiving daily venetoclax until progression of disease, unacceptable toxicity, or elective withdrawal in remission to proceed to allogeneic SCT. Growth factor support, supportive care, and antimicrobial prophylaxis were provided according to institutional standards of care.

On the basis of the experience with CLL, an early amendment implemented strict measures for TLS prophylaxis, monitoring, and management (details provided in protocol; Data Supplement). Briefly, patients were generally treated as outpatients (except for those with MCL with maximum tumor diameter ≥10 cm, who received initial doses as intpatients), with oral or intravenous hydration, allopurinol, and in some cases rasburicase. Patients started at a low dose of venetoclax on day 1, with subsequent intrapatient dose ramp-up (Appendix Table A1, online only). If there was no evidence of TLS, patients received the next higher dose on day 2 or 8, with additional dose increases once per week until target dosing was reached. Laboratory monitoring for TLS was performed at a minimum of 8 and 24 hours postdose at each dose increase.

Study Assessments

Safety. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).11 The following events were reported as DLTs if they occurred during the observation period of the lead-in plus the first 3 weeks at target dosing and were thought to be at least possibly related to venetoclax: grade 4 neutropenia ≥7 days (despite growth factor support), grade 3 to 4 neutropenia with fever, grade 4 thrombocytopenia, grade ≥2 bleeding associated with thrombocytopenia, unexpected grade 2 toxicity that required dose modification or delay of ≥1 week, clinical TLS, or laboratory TLS that did not resolve within 72 hours despite intervention. Venetoclax could be reintroduced with dose reduction when a toxicity had improved to grade ≤1 or baseline if grade 2 at study entry.

Pharmacokinetics. Pharmacokinetic assessments were performed predose at 2, 3, 4, 6, 8, and 24 hours postdose, with additional sampling 8 hours postdose on day 1 of weeks 2 to 5 if the patient was increased to a higher dose.

Exploratory biomarkers. Formalin-fixed, paraffin-embedded tumor samples were evaluated using immunohistochemistry (IHC) for BCL-2 (clone 124) and MYC (clone Y69) from Ventana Medical Systems (Tucson, AZ). BCL-2 immunostaining was scored on a 0 to 3 intensity scale; samples were coded BCL-2 high if ≥50% of lymphoma cells showed a cytoplasmic intensity score of 2+ or 3+ and BCL-2 low if present in <5% of lymphoma cells.12 Samples were coded MYC positive if ≥40% of lymphoma cells showed any level of MYC nuclear staining. DLBCL tumors IHC positive for BCL-2 and MYC were classified as double-expressor (DE) lymphoma.13 Classification of DLBCL tumors into activated B-cell (ABC) or germinal center B-cell (GC) subtypes was determined using the Lymphoma Subtyping Test from NanoString Technologies (Seattle, WA).14 Efficacy. Efficacy end points included overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), time to progression, and overall survival. Responses were assessed according to the 2007 International Working Group or the Fourth International Workshop on Waldenström Macroglobulinemia criteria.15,16 Computed tomography or positron emission tomography with computed tomography was performed at screening, weeks 6, 12 or 16, and 24, and every 12 weeks thereafter. Patients were observed for survival after discontinuation of venetoclax.

Statistical Analysis

All patients who received at least one dose of venetoclax were included in the safety, pharmacokinetics, and survival analyses. Descriptive statistics including medians, standard deviations, and ranges were calculated. The Kaplan-Meier method was used for time-to-event analyses. PFS and DOR data were censored at the time of last tumor assessment in patients who did not experience an event or at time of data cutoff if an assessment was performed after the cutoff. Data were analyzed both by specific dose cohort and by pooling multiple cohorts. Pharmacokinetic parameters were assessed using a noncompartmental approach and biomarker studies by descriptive statistics.

RESULTS

Patient Demographic and Clinical Characteristics

A total of 106 patients with a median age of 66 years (range, 25 to 86 years) were enrolled. Key demographic and clinical
characteristics are summarized in Table 1. Seventy patients were treated in dose-escalation cohorts (target daily dose, 200 to 1,200 mg). Thirty-six patients (DLBCL, n = 21; FL, n = 15) were treated in the safety expansion cohort (target daily dose, 1,200 mg). The median number of prior therapies was three (range, one to 10). Among patients with MCL, none had received ibrutinib or lenalidomide, and five had received prior bortezomib-based therapy. Fifteen patients had received granulocyte colony-stimulating factor (G-CSF) within 6 months of study entry. Approximately half of the patients had bulky lymphadenopathy (> 5 cm, 45%; > 10 cm, 13%) at study entry.

Eighty-seven patients have ended study participation: 77 had progressive disease, three had AEs (anemia, diarrhea and nausea, toxic myopathy), three underwent autologous SCT while in remission, two withdrew consent, one was noncompliant with the protocol, and one was removed at investigator discretion. Thirty-eight deaths have occurred: 10 within 30 days of venetoclax discontinuation (all related to disease progression) and 28 ≥ 30 days after discontinuation (of which 24 were the result of disease progression).

Given the TLS observed in CLL,7 there was particular vigilance for this potential toxicity. Clinical TLS was not observed in the NHL population. Three patients with bulky disease (maximal lymph node diameter, > 10 cm) had laboratory changes meeting Cairo-Bishop criteria for laboratory TLS17 within 24 hours of initial dosing. All three patients received TLS treatment and continued venetoclax as scheduled without dose interruption.

Pharmacokinetics

Venetoclax pharmacokinetics in patients with NHL (Appendix Fig A1, online only) were similar to those in patients with CLL.7 Plasma concentrations peaked approximately 6 to 8 hours after dosing, and the terminal half-life was approximately 16 hours. No trend was observed in dose-normalized steady-state trough levels over time.

Preliminary Efficacy

Of the total 106 patients enrolled, 44% achieved an objective response (complete response [CR] or partial response [PR]). Best response according to histology is summarized in Table 3. Responses were seen in all histologies, with the highest response rate in MCL (ORR, 75% [CR, 21%]). Significant antitumor activity was also observed in other histologies, including FL (ORR, 38% [CR, 14%]), DLBCL (ORR, 18% [CR, 12%]), DLBCL-RT (ORR, 43% [no CRs]), marginal zone lymphoma (MZL; ORR, 67% [no CRs]), and Waldenström macroglobulinemia (WM; ORR, 100% [no CRs]). The median time to first response for all responders was

### Table 1. Patient Demographic and Clinical Characteristics (N = 106)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Patients</th>
<th>MCL (n = 28)</th>
<th>FL (n = 29)</th>
<th>DLBCL* (n = 34)</th>
<th>DLBCL-RT (n = 7)</th>
<th>WM (n = 4)</th>
<th>MZL (n = 3)</th>
<th>Other† (n = 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66</td>
<td>72</td>
<td>64</td>
<td>67</td>
<td>73</td>
<td>67</td>
<td>63</td>
<td>56</td>
</tr>
<tr>
<td>Median</td>
<td>25-86</td>
<td>35-85</td>
<td>46-75</td>
<td>25-86</td>
<td>57-77</td>
<td>58-73</td>
<td>63-67</td>
<td>56-56</td>
</tr>
<tr>
<td>Range</td>
<td>3-7</td>
<td>1-7</td>
<td>1-10</td>
<td>1-8</td>
<td>2-7</td>
<td>3-5</td>
<td>2-6</td>
<td>2-2</td>
</tr>
<tr>
<td>Previous therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Range</td>
<td>1-10</td>
<td>1-7</td>
<td>1-10</td>
<td>1-8</td>
<td>2-7</td>
<td>3-5</td>
<td>2-6</td>
<td>2-2</td>
</tr>
<tr>
<td>Prior ASCT</td>
<td>16</td>
<td>7</td>
<td>2</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Bulky nodes (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 5</td>
<td>48 (45)</td>
<td>14 (50)</td>
<td>8 (28)</td>
<td>17 (50)</td>
<td>5 (71)</td>
<td>2 (50)</td>
<td>1 (100)</td>
<td></td>
</tr>
<tr>
<td>&gt; 10</td>
<td>14 (13)</td>
<td>3 (11)</td>
<td>7 (27)</td>
<td>6 (18)</td>
<td>2 (29)</td>
<td>2 (50)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LDH &gt; upper limit of normal</td>
<td>45 (42)</td>
<td>7 (25)</td>
<td>10 (34)</td>
<td>20 (59)</td>
<td>7 (100)</td>
<td>0</td>
<td>0</td>
<td>1 (100)</td>
</tr>
<tr>
<td>High BCL-2 expression†</td>
<td>41 (46)</td>
<td>13 of 14</td>
<td>14 of 15</td>
<td>9 of 12</td>
<td>1 of 1</td>
<td>3 of 3</td>
<td>1 of 1</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ASCT, autologous stem-cell transplantation; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; RT, Richter transformation; WM, Waldenström macroglobulinemia.

*Includes patients with primary mediastinal B-cell lymphoma (n = 2).
†Proportion of patients with high B-cell leukemia/lymphoma-2 expression by immunohistochemistry (> 50% lymphoma cells scored 2+ or 3+) among those with adequate samples for analysis.
42 days (range, 30 to 366 days; MZL, 36.5; MCL, 38; DLBCL, 39; FL, 40; WM, 74.5; DLBCL-RT, 100 days). The depth of nodal response across different histologies is shown in Figure 1A. For MCL, objective responses were seen even at doses \#800 mg (ORR, 76%, including CR rate of 24%) and not at a higher rate at doses higher than this (Fig 1B). For DLBCL, responses were observed across dose cohorts, but a specific dose threshold for efficacy was not identified (Fig 1C). In FL, objective responses were more frequent at higher doses (> 600 mg), particularly at the 1,200-mg dose (nodal responses, 44%; Fig 1D).

The estimated median PFS for all 106 patients was 6 months (95% CI, 4 to 10), but it varied by histology; for patients with MCL, FL, and DLBCL, it was 14, 11, and 1 months, respectively (Fig 2A). DOR for the four patients with WM was 11.1, 12.4, 38.2, and 41.5 months, and for the two patients with MZL, it was 2.3 and 23.6 months, respectively. The estimated 12-month overall survival for all patients was 70%, and it was 100%, 82%, and 32% for those with FL, MCL, and DLBCL, respectively (Fig 2B). Patients with MCL or FL who achieved CRs had more durable responses than those who achieved PRs as best response (Figs 2C and 2D). Three patients with chemotherapy-refractory disease,
including DLBCL, primary mediastinal large B-cell lymphoma, and MCL, proceeded to allogeneic SCT after achieving remission with venetoclax (CR, PR, and PR, respectively); all three patients remained disease free without further treatment at 24.5, 24.5, and 22.7 months, respectively, after transplantation during the protocol-defined follow-up period of 2 years after venetoclax discontinuation. At the time of data cutoff, 19 patients continued to receive study treatment and derive clinical benefit (Fig 3).

Exploratory Biomarkers

Baseline tissue was available from 46 patients; 41 samples (89%) were BCL-2 high by IHC. BCL-2 expression according to histology is summarized in Table 1. High expression was observed in all histologies, including MCL (13 [93%] of 14), FL (14 [93%] of 15), DLBCL (nine [75%] of 12), and WM (three [100%] of three), but did not correspond to observed responses. The ORR was similar in patients with BCL-2 low and BCL-2 high expression based on IHC staining (Appendix Table A2, online only). Cell-of-origin molecular subtype was determined for the five baseline DLBCL tumor samples that were available. Four patients had a GCB subtype, and one patient had an ABC subtype. CRs were observed in one patient each with ABC and GCB subtypes (Appendix Table A3, online only). BCL-2 and MYC lymphoma was observed in four of six evaluable DLBCL tumors. Two patients with DE lymphoma achieved an objective response (CR, n = 1; PR, n = 1; Appendix Table A4, online only). All five patients with DLBCL with sufficient tissue for fluorescent in situ hybridization analysis were negative for BCL-2 and MYC rearrangements. Two other patients had double-hit DLBCL noted in prior pathology reports, and neither patient achieved a response to venetoclax.

**DISCUSSION**

Venetoclax was well tolerated in patients with relapsed or refractory NHL. The high level of selectivity of venetoclax for BCL-2 was evident in the response patterns observed across different histologies.
led to enhanced antilymphoma activity without the dose-limiting thrombocytopenia observed with its predecessor navitoclax, a less selective BH3 mimetic. No clinical TLS was observed with starting doses of up to 400 mg daily (the dose now being used for studies of venetoclax in patients with CLL) or with ongoing dosing at 1,200 mg daily. Only three patients with high tumor burden had evidence of laboratory TLS, and all were managed successfully with intravenous fluids, corrective measures, and continuation of allopurinol. These results suggest that for NHL subtypes other than MCL, a dosing strategy starting at 400 mg daily for 1 week followed by weekly ramp-up from 800 mg daily to 1,200 mg daily thereafter with outpatient monitoring for TLS is well tolerated. Patients with high tumor burden, particularly those with MCL, are at increased risk for TLS and may be best managed with a more conservative dosing strategy, including a starting dose of 100 mg daily for 1 week, followed by weekly ramp-up to 200, 400, and 800 mg daily.

The other toxicities of venetoclax were mild and included mostly low-grade GI toxicity and neutropenia. The latter is likely an on-target effect of BCL-2 inhibition in neutrophil precursors and was well managed with supportive care including growth factor support administered concomitantly with treatment or dose interruption. Because a > 30% DLT rate was not seen at any dose level tested, no formal MTD was determined. The recommended phase II dose was therefore determined by the investigators to be the maximum cleared dose for FL and DLBCL (1,200 mg) and for DLBCL-RT (600 mg). For MCL, 800 mg was chosen given the significant activity observed at this dose and the risk of incremental toxicity at higher doses.

Venetoclax demonstrated significant single-agent activity across a broad range of NHL subtypes. The highest response rate was seen in MCL, with 75% of patients achieving responses, including 21% achieving CRs. Patients with MCL had a median PFS of 14 months, with only one progression to date among six complete responders and some patients receiving treatment > 33 months. These results are similar to those seen in MCL with the Bruton tyrosine kinase inhibitor ibrutinib (ORR, 68% [CR, 21%]; median PFS, 13.9 months).

Patients with FL had a 38% response rate, with 14% achieving CRs, and a median PFS of 11 months, similar to the results seen with the delta isoform–specific phosphatidylinositol-3-kinase inhibitor idelalisib in FL (ORR, 47% to 57%; PFS, 7.6 to 11 months). Higher response rates were seen with higher doses of venetoclax in FL; the ORR was 44% for the 18 patients treated at 1,200 mg compared with an ORR of 27% for the 11 patients treated at ≤ 900 mg. These preliminary results need to be explored further in additional studies.
The response rate for patients with DLBCL was 18%, and unlike in FL, it did not seem to vary based on cohort dose. Nevertheless, four patients achieved CRs, including two patients who went on to undergo allogeneic SCT and remain in complete remission now > 2 years after transplantation. B-cell receptor pathway antagonists have shown limited efficacy in DLBCL, and therefore, novel agents such as venetoclax are urgently needed for combination regimens. Cell-of-origin data were only available in five patients with DLBCL, which is a limitation of this study. Significant responses to venetoclax were also noted in patients with MZL and WM, supporting the exploration of venetoclax in future studies in these diseases.

Understanding the heterogeneity of clinical responses observed will require further exploration. In the CLL arm, the depth of initial response to venetoclax was associated with the level of mitochondrial priming for apoptosis as determined by the BH3 profiling assay. Correlative samples were limited in the NHL arm and did not allow for systematic evaluation of parameters such as antiapoptotic family protein or mRNA expression, mutational analysis, or BH3 profiling. Exploratory analysis of the level of BCL-2 expression by IHC showed no significant association with clinical response or TLS risk in this patient group, where all patient samples tested had some BCL-2 expression. These results indicate that BCL-2 protein expression alone is not an adequate biomarker to predict clinical response or TLS risk, and functional assessments of the relative balance of the anti- and proapoptotic BCL-2 family proteins should be explored as biomarkers. Additional biomarker investigations will be important in future studies of venetoclax in NHL.

The optimal combination partners for venetoclax in NHL remain to be defined, and studies are under way to assess the safety and efficacy of combining venetoclax with chemotherapy, monoclonal antibodies, and B-cell receptor signaling inhibitors. Preclinical data suggest that abbreviated venetoclax use in combination with DNA-damaging cytotoxic therapies may be sufficient to achieve durable remissions. Combination with rituximab augmented the efficacy of the less selective BCL-2 inhibitor navitoclax in FL, and similar studies with venetoclax are ongoing.

We conclude that venetoclax is active as a single agent in NHL, with clinical benefit varying depending on histologic subtype. Targeted inhibition of BCL-2 will likely have a greater clinical impact when venetoclax is combined with other agents. The favorable toxicity profile and unique mechanism of action suggest that venetoclax will be a logical partner in a range of combination regimens. Ongoing trials will define the optimal use of venetoclax in NHL.

Fig 3. Patient status during study by histology, including mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), DLBCL with Richter transformation (RT), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Right arrows indicate patients who continue to receive active treatment.

Authors’ Disclosures of Potential Conflicts of Interest
Disclosures provided by the authors are available with this article at jco.org.

Author Contributions
Conception and design: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, Rod A. Humerickhouse
Financial support: Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori Gressick, Franklin Peale, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, Gary B. Gordon
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
Venetoclax Monotherapy in Patients With NHL


Affiliations

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

Support

Supported by AbbVie (which also funded editorial support) and Genentech; in part by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant No. P30 CA008748 (J.F.G.); and in part by a Career Development Award from the American Society of Clinical Oncology (M.S.D.).

Prior Presentation

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Matthew S. Davids
Consulting or Advisory Role: Infinity Pharmaceuticals, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Pharmacyclics, TG Therapeutics, Celgene, AbbVie
Research Funding: Genentech (Inst), TG Therapeutics (Inst), Infinity Pharmaceuticals (Inst), Pharmacyclics (Inst), AbbVie (Inst)

Andrew W. Roberts
Research Funding: AbbVie (Inst), Genentech (Inst), Amgen (Inst), BeiGene (Inst), Servier Laboratories (Inst)

John F. Seymour
Consulting or Advisory Role: Roche, Genentech
Speakers Bureau: Roche, Genentech
Research Funding: AbbVie, Genentech

John M. Pagel
Consulting or Advisory Role: Pharmacyclics, Gilead Sciences

Brad S. Kahl
Consulting or Advisory Role: AbbVie, Celgene, Genentech, Millennium, Pharmacyclics, Seattle Genetics
Research Funding: AbbVie, Genentech

William G. Wierda
Consulting or Advisory Role: Sanoft, Genentech, Pharmacyclics, Celgene, Gilead Sciences, GlaxoSmithKline, Novartis, Genzyme, Merck, AbbVie, Emergent BioSolutions
Research Funding: GlaxoSmithKline, Novartis, AbbVie, Genentech, Karyopharm Therapeutics, Pharmacyclics, Acerta Pharma, Gilead Sciences, Janssen Pharmaceuticals, Emergent BioSolutions, Juno Therapeutics, Kite Pharma

Soham Puvvada
Consulting or Advisory Role: AbbVie, Genentech, Pharmacyclics, Seattle Genetics
Speakers Bureau: Gilead Sciences
Research Funding: Spectrum Pharmaceuticals (Inst), AbbVie (Inst), Genentech (Inst), Seattle Genetics (Inst), Takeda Pharmaceuticls (Inst), Janssen Pharmaceuticals (Inst)

John F. Gerecitano
Honoraria: Genentech, AbbVie, Bayer HealthCare Pharmaceuticals, Gilead Sciences, Samus Therapeutics
Consulting or Advisory Role: Genentech, AbbVie, Bayer HealthCare Pharmaceuticals, Gilead Sciences, Samus Therapeutics

© 2017 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Downloaded from ascopubs.org by The University of Arizona on March 31, 2017 from 150.135.118.031
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Acknowledgment

We thank the patients and their families, study coordinators, and support staff. Editorial support was provided by Sharanya Ford, of AbbVie, and by Evidence Scientific Solutions (Philadelphia, PA) and funded by AbbVie. Data programming and analysis support was provided by Joseph Beason.

Appendix

Table A1. Intrapatient Ramp-Up Scheme in Arm B of the M12-175 Study

<table>
<thead>
<tr>
<th>Study Cohort</th>
<th>No. of Patients</th>
<th>Dosing Regimen (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose escalation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B1</td>
<td>3</td>
<td>50-100</td>
</tr>
<tr>
<td>B2</td>
<td>3</td>
<td>100-200</td>
</tr>
<tr>
<td>B3</td>
<td>4</td>
<td>200-300</td>
</tr>
<tr>
<td>B4</td>
<td>8</td>
<td>200-400</td>
</tr>
<tr>
<td>B5</td>
<td>10</td>
<td>300-600</td>
</tr>
<tr>
<td>B6*</td>
<td>4</td>
<td>400-900</td>
</tr>
<tr>
<td>B7a MCL</td>
<td>7</td>
<td>20-50-100-200</td>
</tr>
<tr>
<td>B7b NHL</td>
<td>4</td>
<td>300-400-600</td>
</tr>
<tr>
<td>B8a MCL</td>
<td>7</td>
<td>20-50-100-200</td>
</tr>
<tr>
<td>B8b NHL</td>
<td>9</td>
<td>400-800-1200</td>
</tr>
<tr>
<td>B8c DLBCL-RT</td>
<td>5</td>
<td>20-50-100-200</td>
</tr>
<tr>
<td>B9a MCL</td>
<td>6</td>
<td>100-200-400-800</td>
</tr>
<tr>
<td><strong>Safety expansion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FL and de novo DLBCL</td>
<td>36</td>
<td>400-800-1,200</td>
</tr>
</tbody>
</table>

NOTE. Patients in each dose-escalation cohort and the safety expansion cohort were started at the lowest dose and escalated to the target dose (indicated by bold font). In cohort B6, TLS events that occurred in the CLL arm of this study led to a modified, more gradual dose ramp-up schedule. Patients with MCL were expected to show similarity to patients with CLL, and thus, their ramp-up schedule mimicked that for CLL, and beginning with cohort B7, patients followed one of two ramp-up schedules. Similarly, patients with RT followed a ramp-up scheme identical to that for patients with CLL. Two patients with DLBCL-RT were previously enrolled in cohort B5, which had a maximum dose of 600 mg, and five patients with DLBCL-RT were enrolled in cohort B8c, which followed the revised CLL dosing schedule, with a maximum dose of 400 mg.

Abbreviations: CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma (including marginal zone lymphoma and Waldenstrom macroglobulinemia); RT, Richter transformation; TLS, tumor lysis syndrome.

*One patient in cohort B6 had MCL; this patient started with a lower dose of 200 mg and then ramped up to 400 and then 800 mg.
### Table A2. Summary of Objective Responses and PFS by BCL-2 Expression Data (n = 46)

<table>
<thead>
<tr>
<th>BCL-2 Expression Status*</th>
<th>Total Patients</th>
<th>Best Response</th>
<th>ORR (%)†</th>
<th>Mean PFS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (1+)</td>
<td>5</td>
<td>2</td>
<td>0</td>
<td>40</td>
</tr>
<tr>
<td>High (≥ 2+)</td>
<td>41</td>
<td>6</td>
<td>13</td>
<td>46</td>
</tr>
<tr>
<td>2+</td>
<td>12</td>
<td>1</td>
<td>4</td>
<td>42</td>
</tr>
<tr>
<td>3+</td>
<td>29</td>
<td>5</td>
<td>9</td>
<td>48</td>
</tr>
</tbody>
</table>

Abbreviations: BCL-2, B-cell leukemia/lymphoma-2; CR, complete response; IHC, immunohistochemistry; ORR, overall response rate; PFS, progression-free survival; PR, partial response.

* BCL-2 staining was scored on a 0 to 3 intensity scale, and samples were coded BCL-2 high if ≥ 50% of tumor cells showed a cytoplasmic intensity score of 2+ or 3+. An IHC score of 2+ was assigned if lymphoma cells had a staining intensity equal to the predominant intensity of cytoplasmic staining in the mantle zone B cells and paracortical T cells found in tonsils, which served as positive control tissue. Specimens with a signal weaker or stronger than 2+ were assigned an intensity of 1+ or 3+, respectively. Samples with an intensity of 1+ were coded as BCL-2 low; no tissue sample had an IHC intensity score of 0 among the 46 patients with samples for analysis.

† Percentage of patients achieving either CR or PR.

### Table A3. Objective Responses by DLBCL COO Subtype

<table>
<thead>
<tr>
<th>Patient</th>
<th>Histology</th>
<th>LST Linear Predictor Score</th>
<th>COO Subtype</th>
<th>Best Objective Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DLBCL</td>
<td>-69.4</td>
<td>GCB</td>
<td>PD</td>
</tr>
<tr>
<td>2</td>
<td>DLBCL</td>
<td>2,895.2</td>
<td>ABC</td>
<td>CR</td>
</tr>
<tr>
<td>3</td>
<td>DLBCL</td>
<td>819.9</td>
<td>GCB</td>
<td>SD</td>
</tr>
<tr>
<td>4</td>
<td>DLBCL</td>
<td>1,042</td>
<td>GCB</td>
<td>SD</td>
</tr>
<tr>
<td>5</td>
<td>DLBCL</td>
<td>1,214</td>
<td>GCB</td>
<td>CR</td>
</tr>
</tbody>
</table>

Abbreviations: ABC, activated B cell; COO, cell of origin; CR, complete response; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell; LST, lymphoma subtype test; PD, progressive disease; SD, stable disease.

### Table A4. Objective Responses by BCL-2 and MYC DE Subtype

<table>
<thead>
<tr>
<th>Patient</th>
<th>Histology</th>
<th>IHC</th>
<th>BCL-2*</th>
<th>MYC (%)†</th>
<th>Subtype</th>
<th>Best Objective Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DLBCL-RT</td>
<td>3+</td>
<td>40</td>
<td></td>
<td>DE</td>
<td>PR</td>
</tr>
<tr>
<td>2</td>
<td>DLBCL</td>
<td>3+</td>
<td>100</td>
<td></td>
<td>DE</td>
<td>PD</td>
</tr>
<tr>
<td>3</td>
<td>DLBCL</td>
<td>3+</td>
<td>80</td>
<td></td>
<td>DE</td>
<td>PD</td>
</tr>
<tr>
<td>4</td>
<td>DLBCL</td>
<td>3+</td>
<td>90</td>
<td></td>
<td>DE</td>
<td>CR</td>
</tr>
<tr>
<td>5</td>
<td>DLBCL</td>
<td>3+</td>
<td>30</td>
<td>Non-DE</td>
<td></td>
<td>SD</td>
</tr>
<tr>
<td>6</td>
<td>DLBCL</td>
<td>1+</td>
<td>20</td>
<td>Non-DE</td>
<td></td>
<td>PD</td>
</tr>
</tbody>
</table>

Abbreviations: BCL-2, B-cell leukemia/lymphoma-2; CR, complete response; DE, double expressor; DLBCL, diffuse large B-cell lymphoma; IHC, immunohistochemistry; PD, progressive disease; PR, partial response; RT, Richter transformation; SD, stable disease.

* BCL-2 staining was scored on a 0 to 3 intensity scale, and samples were coded BCL-2 high if ≥ 50% of tumor cells showed a cytoplasmic intensity score of 2+ or 3+. An IHC score of 2+ was assigned if lymphoma cells had a staining intensity equal to the predominant intensity of cytoplasmic staining in the mantle zone B cells and paracortical T cells found in tonsils, which served as positive control tissue. Specimens with a signal weaker or stronger than the latter 2+ score were assigned an intensity of 1+ or 3+, respectively.

† Samples were coded MYC positive if ≥ 40% of tumor cells showed any level of MYC nuclear staining above background.
Fig A1. Mean venetoclax plasma concentration. Time profiles in (A, B) dose-escalation and (C, D) safety expansion cohorts according to (A, C) linear and (B, D) log-linear scales. Error bars represent standard deviations.